CN1700923B - 多取代的选择性雄激素受体调节剂及其使用方法 - Google Patents

多取代的选择性雄激素受体调节剂及其使用方法 Download PDF

Info

Publication number
CN1700923B
CN1700923B CN038096064A CN03809606A CN1700923B CN 1700923 B CN1700923 B CN 1700923B CN 038096064 A CN038096064 A CN 038096064A CN 03809606 A CN03809606 A CN 03809606A CN 1700923 B CN1700923 B CN 1700923B
Authority
CN
China
Prior art keywords
androgen receptor
compound
another embodiment
receptor modulator
selective androgen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN038096064A
Other languages
English (en)
Chinese (zh)
Other versions
CN1700923A (zh
Inventor
詹姆斯·T.·多尔顿
杜安·D.·米勒
米切尔·S.·斯坦纳
卡伦·A.·韦韦尔卡
黄东晋
陈纪云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Priority claimed from PCT/US2003/003123 external-priority patent/WO2003074449A2/en
Publication of CN1700923A publication Critical patent/CN1700923A/zh
Application granted granted Critical
Publication of CN1700923B publication Critical patent/CN1700923B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
CN038096064A 2002-02-28 2003-02-24 多取代的选择性雄激素受体调节剂及其使用方法 Expired - Fee Related CN1700923B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45373602P 2002-02-28 2002-02-28
US60/453,736 2002-02-28
US42338102P 2002-11-04 2002-11-04
US60/423,381 2002-11-04
PCT/US2003/003123 WO2003074449A2 (en) 2002-02-28 2003-02-24 Multi-substitued selective androgen receptor modulators and methods of use thereof

Publications (2)

Publication Number Publication Date
CN1700923A CN1700923A (zh) 2005-11-23
CN1700923B true CN1700923B (zh) 2011-06-15

Family

ID=33422848

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038096064A Expired - Fee Related CN1700923B (zh) 2002-02-28 2003-02-24 多取代的选择性雄激素受体调节剂及其使用方法

Country Status (7)

Country Link
US (1) US7705182B2 (https=)
EP (1) EP1487458B1 (https=)
JP (2) JP5113979B2 (https=)
KR (2) KR101088352B1 (https=)
CN (1) CN1700923B (https=)
AT (1) ATE533494T1 (https=)
ES (1) ES2528764T3 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106748884A (zh) * 2016-12-13 2017-05-31 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
ES2581765T3 (es) * 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ(アミノ酸)ターゲッティング部分
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CN103553966B (zh) * 2007-09-11 2016-09-07 Gtx公司 选择性雄激素受体调节剂的固体形态
EP2436376B1 (en) 2007-09-28 2014-07-09 BIND Therapeutics, Inc. Cancer cell targeting using nanoparticles
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8791158B2 (en) * 2010-01-11 2014-07-29 Gtx, Inc. Methods of treating meibomian gland dysfunction
EP2604668A1 (en) 2010-08-11 2013-06-19 Asahi Glass Company, Limited Water- and oil-repellent agent composition and article
US8395552B2 (en) 2010-11-23 2013-03-12 Metamagnetics, Inc. Antenna module having reduced size, high gain, and increased power efficiency
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
AU2015331756A1 (en) * 2014-10-16 2017-05-04 Gtx, Inc. Methods of treating urological disorders using SARMs
CN109134533B (zh) * 2017-06-27 2020-08-11 维眸生物科技(上海)有限公司 一种含磷化合物及其制备和应用
WO2019001171A1 (zh) * 2017-06-27 2019-01-03 维眸生物科技上海有限公司 一种含磷化合物及其制备和应用
JP2021523151A (ja) 2018-05-11 2021-09-02 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子
KR20230084476A (ko) 2020-10-08 2023-06-13 타르그이뮨 테라퓨틱스 아게 암의 치료를 위한 면역요법
WO2023079142A2 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
IL320615A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag PSMA-targeting linear conjugates containing polyethyleneimine and polyethylene glycol and polyplexes containing the same materials
US20260000700A1 (en) 2022-11-07 2026-01-01 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
IL320618A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
CN120641107A (zh) * 2022-11-17 2025-09-12 维眸生物科技(浙江)有限公司 用于治疗炎症性肠病的含磷化合物
WO2025238236A1 (en) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636505A (en) * 1982-07-23 1987-01-13 Imperial Chemical Industries Plc Amide derivatives

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB136001A (en) 1919-01-11 1919-12-11 Frank Harrison An Adjustable Angle, and Surface-marking Plate.
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (en) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
US4633025A (en) 1985-04-15 1986-12-30 Miles Laboratories, Inc. Method for preparing (+)R-2-methyl-hexane-1,2-diol
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US4977288A (en) 1988-01-29 1990-12-11 President And Fellows Of Harvard College M-aminophenyltrialkylstannane
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
AU1687395A (en) 1994-01-21 1995-08-08 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
EP1043325B1 (en) 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
PT918774E (pt) 1996-06-27 2002-05-31 Ligand Pharm Inc Compostos moduladores do receptor para androgenio e metodos
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6160011A (en) 1997-05-30 2000-12-12 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
WO1998055153A1 (en) 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
RU2234920C2 (ru) 1999-06-11 2004-08-27 Уотсон Фармасьютикалс, Инк. Введение непероральным путем андрогенных стероидов женщинам
AU775928B2 (en) 1999-10-14 2004-08-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
HUP0203785A2 (hu) 1999-10-19 2003-04-28 Nobex Corporation Eljárás Casodex enantiomereinek, származékainak és intermediereinek előállítására
CN1413188A (zh) 1999-10-27 2003-04-23 诺贝克斯公司 基本纯的比卡鲁胺合成中中间体的拆分
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
RU2003102390A (ru) 2000-06-28 2004-05-27 Бристол-Маерс Сквибб Компани (Us) Селективные модуляторы рецептора андрогена и способы их идентификации, изготовления и применения
MXPA02012605A (es) 2000-06-28 2003-05-14 Squibb Bristol Myers Co Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
US6998500B2 (en) * 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
DE60137728D1 (de) * 2000-08-24 2009-04-02 Univ Tennessee Res Foundation Selektive Modulatoren des Androgenrezeptors und Methoden zu deren Verwendung
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
DK1463497T3 (da) 2001-12-06 2012-01-30 Gtx Inc Behandling af muskelsvind med selektive androgenreceptormodulatorer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636505A (en) * 1982-07-23 1987-01-13 Imperial Chemical Industries Plc Amide derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WO 9855153 A,说明书第6-8页.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106748884A (zh) * 2016-12-13 2017-05-31 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法
CN106748884B (zh) * 2016-12-13 2021-08-20 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法

Also Published As

Publication number Publication date
US20060183931A1 (en) 2006-08-17
JP2005526741A (ja) 2005-09-08
KR20100103662A (ko) 2010-09-27
ATE533494T1 (de) 2011-12-15
KR101088352B1 (ko) 2011-11-30
US7705182B2 (en) 2010-04-27
ES2528764T3 (es) 2015-02-12
CN1700923A (zh) 2005-11-23
JP2010180245A (ja) 2010-08-19
JP5113979B2 (ja) 2013-01-09
EP1487458A4 (en) 2006-07-26
EP1487458B1 (en) 2011-11-16
EP1487458A2 (en) 2004-12-22
KR20040101251A (ko) 2004-12-02

Similar Documents

Publication Publication Date Title
CN1700923B (zh) 多取代的选择性雄激素受体调节剂及其使用方法
CN100537520C (zh) N-桥连选择性雄激素受体调节剂及其使用方法
CN1726185B (zh) 卤代选择性雄激素受体调节剂及其使用方法
US7803970B2 (en) Multi-substitued selective androgen receptor modulators and methods of use thereof
US7253210B2 (en) Methylene-bridged selective androgen receptor modulators and methods of use thereof
CA2477737C (en) Multi-substituted selective androgen receptor modulators and methods of use thereof
US20060004042A1 (en) Formulations comprising selective androgen receptor modulators
US20040147489A1 (en) Haloacetamide and azide substituted compounds and methods of use thereof
US20050038110A1 (en) Selective androgen receptor modulators and methods of use thereof
US20040138244A1 (en) Heterocyclic selective androgen receptor modulators and methods of use thereof
US20040167103A1 (en) Haloacetamide and azide substituted compounds and methods of use thereof
AU2008201811B2 (en) Multi-substituted selective androgen receptor modulators and methods of use thereof
EP2266577B1 (en) Multi-substituted selective androgen receptor modulators and methods of use therof
KR20040105208A (ko) 할로아세트아미드 및 아지드 치환 화합물 및 그의 용도
HK1152492A (en) Multi-substitued selective androgen receptor modulators and methods of use therof
HK1156298A (en) Selective androgen receptor modulators and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110615

Termination date: 20130224